Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year

Skye Bioscience, Inc. (NASDAQ:SKYE) on Monday shared interim 52-week data from the combination therapy arms in the extension phase of the Phase 2a CBeyond proof-of-concept study of nimacimab.Skye Phase 2a clinical trial (NCT06577090) in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy).Interim Data SummaryThe blinded extension of the CBeyond study for combination cohorts ...